[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stage-ii-endometrial-cancer\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stage-ii-endometrial-cancer":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":5},"100597709",false,"NCT07062016","Molecular and ctDNA Characterization of High-Risk Endometrial Cancer","MC230601 Molecular and ctDNA Characterization of High-Risk Endometrial Cancer","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Planned complete surgical staging at Mayo Clinic. Complete surgical staging includes at least total hysterectomy, bilateral salpingo-oophorectomy and lymph node assessment. Sentinel node mapping meets the criteria for lymph node assessment. Peritoneal cytology is recommended. Additional staging procedures such as pelvic and para-aortic nodal evaluation, omental biopsy or omentectomy, may also be utilized for staging in patients based on the clinical situation and at the surgeon's discretion\n* At least one preoperative or postoperative feature of aggressive disease \\[International Federation of Gynecology and Obstetrics (FIGO) staging used throughout this protocol\\]\n\n  * Preoperatively:\n\n    * Biopsy with grade 3 endometrioid endometrial cancer (EC) or non-endometrioid EC\n    * Patients with FIGO grade 1-2 EC with evidence of extrauterine disease on imaging (CT, MRI, or PET)\n  * Postoperatively:\n\n    * Endometrial cancer (FIGO) with one or more established risk factors:\n\n      * Non-endometrioid histology\n\n        * Grade 3\n      * Lymphovascular space invasion (LVSI), ≥ 50% of myometrial invasion, presence of isolated tumor cells (ITC) in a sentinel lymph node OR\n      * Stage II to IV (FIGO) EC\n* Provide written informed consent\n* Willingness to provide mandatory blood specimens for correlative research\n* Willingness to provide mandatory tissue specimens for correlative research\n* Willingness to return to registering site for clinical follow-up\n\nExclusion Criteria:\n\n* Patient receiving or who has received neoadjuvant chemotherapy\n* Pre-operative pregnancy","FEMALE","18 Years",{"count":18,"type":19},100,"ESTIMATED","OBSERVATIONAL","This study seeks to better understand the recurrence of high-risk endometrial cancer. It will collect information about cancer genetics to find out various hereditary or cancer specific genetic variants that may have a role in diagnosis or management and prognosis of cancer. It also seeks to develop a genetic results and medical record databank for future studies.",[23,24,25,26,27],"Endometrial Carcinoma","Endometrial High Grade Endometrioid Adenocarcinoma","Stage II Endometrial Cancer","Stage III Endometrial Cancer","Stage IV Endometrial Cancer","RECRUITING","2026-04-09",{"date":31,"type":32},"2026-04-13","ACTUAL",{"date":34,"type":32},"2025-10-01",{"date":36,"type":19},"2028-10-31",{"name":38,"class":39},"Mayo Clinic","OTHER",""]